Is the Options Market Predicting a Spike in ACADIA Pharmaceuticals (ACAD) Stock?

13.02.25 14:30 Uhr

Werte in diesem Artikel
Aktien

14,41 EUR -0,34 EUR -2,31%

Indizes

16.550,6 PKT -1.050,4 PKT -5,97%

Investors in Acadia Pharmaceuticals Inc. ACAD need to pay close attention to the stock based on moves in the options market lately. That is because the Mar 21, 2025 $12 Put had some of the highest implied volatility of all equity options today. What is Implied Volatility?Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy.What do the Analysts Think?Clearly, options traders are pricing in a big move for ACADIA Pharmaceuticals shares, but what is the fundamental picture for the company? Currently, ACADIA Pharmaceuticals is a Zacks Rank #3 (Hold) in the Medical - Biomedical and Genetics industry that ranks in the Top 29% of our Zacks Industry Rank. Over the last 60 days, the Zacks Consensus Estimate for the current quarter has moved from 22 cents per share to 19 cents in that period.Given the way analysts feel about ACADIA Pharmaceuticals right now, this huge implied volatility could mean there’s a trade developing. Oftentimes, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected.Looking to Trade Options?Check out the simple yet high-powered approach that Zacks Executive VP Kevin Matras has used to close recent double and triple-digit winners. In addition to impressive profit potential, these trades can actually reduce your risk.Click to see the trades now >>Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

In eigener Sache

Übrigens: ACADIA Pharmaceuticals und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.

Ausgewählte Hebelprodukte auf ACADIA Pharmaceuticals

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf ACADIA Pharmaceuticals

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu ACADIA Pharmaceuticals Inc.

Wer­bung

Analysen zu ACADIA Pharmaceuticals Inc.

DatumRatingAnalyst
23.07.2019ACADIA Pharmaceuticals BuyNeedham & Company, LLC
10.12.2018ACADIA Pharmaceuticals HoldCanaccord Adams
07.08.2018ACADIA Pharmaceuticals HoldStifel, Nicolaus & Co., Inc.
20.07.2016ACADIA Pharmaceuticals BuyH.C. Wainwright & Co.
07.08.2015ACADIA Pharmaceuticals BuyNeedham & Company, LLC
DatumRatingAnalyst
23.07.2019ACADIA Pharmaceuticals BuyNeedham & Company, LLC
07.08.2018ACADIA Pharmaceuticals HoldStifel, Nicolaus & Co., Inc.
20.07.2016ACADIA Pharmaceuticals BuyH.C. Wainwright & Co.
07.08.2015ACADIA Pharmaceuticals BuyNeedham & Company, LLC
12.03.2015ACADIA Pharmaceuticals BuyNeedham & Company, LLC
DatumRatingAnalyst
10.12.2018ACADIA Pharmaceuticals HoldCanaccord Adams
06.08.2008ACADIA Pharmaceuticals market performJMP Securities LLC
08.07.2008ACADIA Pharmaceuticals UpgradeBanc of America Securities LLC
17.06.2008ACADIA Pharmaceuticals DowngradeJefferies & Company Inc.
17.06.2008ACADIA Pharmaceuticals DowngradeFriedman, Billings, Ramsey Group, Inc.
DatumRatingAnalyst
01.09.2009ACADIA Pharmaceuticals sell Citigroup Corp.
18.06.2008ACADIA Pharmaceuticals sellBanc of America Securities LLC
06.05.2008ACADIA Pharmaceuticals sellBrean Murray, Carret & Co., LLC
06.11.2007ACADIA Pharmaceuticals sellBrean Murray, Carret & Co., LLC

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für ACADIA Pharmaceuticals Inc. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen